Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
ALNY

Alnylam

$127.51

1.13 (0.89%)

, SNY

Sanofi

$44.54

-0.11 (-0.25%)

07:03
11/20/17
11/20
07:03
11/20/17
07:03
Hot Stocks
Alnylam receives FDA breakthrough therapy designation for Patisiran »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$127.51

1.13 (0.89%)

SNY

Sanofi

$44.54

-0.11 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

Friday
ALNY

Alnylam

$126.38

0.43 (0.34%)

06:01
11/17/17
11/17
06:01
11/17/17
06:01
Recommendations
Alnylam analyst commentary at Piper Jaffray »

Piper trims Alnylam…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

  • 14

    Nov

Thursday
ALNY

Alnylam

$125.95

-4.37 (-3.35%)

, SNY

Sanofi

$44.66

0.01 (0.02%)

07:18
11/16/17
11/16
07:18
11/16/17
07:18
Hot Stocks
Alynlam initiates rolling submission of NDA to FDA for Patisiran »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$125.95

-4.37 (-3.35%)

SNY

Sanofi

$44.66

0.01 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

  • 14

    Nov

Over a week ago
ALNY

Alnylam

$129.11

-10.87 (-7.77%)

22:04
11/13/17
11/13
22:04
11/13/17
22:04
Syndicate
Alnylam 5.6M share Secondary priced at $125 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

  • 14

    Nov

ALNY

Alnylam

$139.98

2.3 (1.67%)

, SNY

Sanofi

$45.00

-0.42 (-0.92%)

07:31
11/13/17
11/13
07:31
11/13/17
07:31
Hot Stocks
Alnylam granted accelerated assessment for patisiran by EMA »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$139.98

2.3 (1.67%)

SNY

Sanofi

$45.00

-0.42 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

ALNY

Alnylam

$139.98

2.3 (1.67%)

07:08
11/13/17
11/13
07:08
11/13/17
07:08
Syndicate
Alnylam files to sell $675M in common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

ALNY

Alnylam

$132.33

2.83 (2.19%)

05:24
11/09/17
11/09
05:24
11/09/17
05:24
Upgrade
Alnylam rating change at JPMorgan »

Alnylam upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

ALNY

Alnylam

$129.50

-1 (-0.77%)

05:01
11/08/17
11/08
05:01
11/08/17
05:01
Recommendations
Alnylam analyst commentary at Barclays »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

ALNY

Alnylam

$129.50

-1 (-0.77%)

16:07
11/07/17
11/07
16:07
11/07/17
16:07
Hot Stocks
Alnylam plans for Partisiran NDA by year end »

Advanced patisiran, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 07

    Nov

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

ALNY

Alnylam

16:03
11/07/17
11/07
16:03
11/07/17
16:03
Earnings
Alnylam reports Q3 EPS ($1.06), consensus ($1.27) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 28

    Nov

  • 29

    Nov

  • 14

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.